Eko Low Ejection Fraction Tool (ELEFT) vs FibriCheck

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VS
by FibriCheck

AI Verdict

Eko Low Ejection Fraction Tool (ELEFT) is designed for clinicians to detect low ejection fraction during physical exams using integrated digital stethoscopes. In contrast, FibriCheck is a patient-facing mobile application for remote monitoring and detection of arrhythmias via smartphone. While both utilize AI for cardiac health, their specific target conditions, technological approaches, and primary user workflows are distinct.

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if your clinical practice requires an integrated, point-of-care AI solution to screen for low ejection fraction during routine physical examinations. This tool is ideal for clinicians seeking to proactively identify early indicators of heart failure risk non-invasively within seconds using a digital stethoscope.

View Eko Low Ejection Fraction Tool (ELEFT) →

Choose FibriCheck if…

Choose FibriCheck if you need a flexible, patient-centric solution for remote heart rhythm monitoring and arrhythmia detection using a smartphone. This tool is best suited for empowering patients to self-monitor their cardiac health and for healthcare providers to remotely track and manage patients with suspected or diagnosed arrhythmias like AFib.

View FibriCheck →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Eko Low Ejection Fraction Tool (ELEFT) FibriCheck
Pricing Unknown Subscription-based, with options for monthly or annual payments. prices vary by region and may be partly or fully covered by insurance or employer.
Deployment Unknown Cloud-based (private cloud).
FDA Status Cleared AI-estimated Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT integrates seamlessly into a clinician's existing workflow by enhancing a standard stethoscope during routine physical exams, requiring minimal change to established procedures. FibriCheck, while accessible via smartphone, relies on patient engagement for data collection, which can introduce variability in adherence and proper use from a clinical workflow perspective.

Clinical Value

Tie

Both tools offer significant clinical value in their respective domains. ELEFT provides early detection of low ejection fraction, a key indicator of heart failure, during routine exams. FibriCheck offers continuous monitoring and detection of arrhythmias, including AFib, which is crucial for managing chronic cardiac conditions and preventing complications. Both are FDA-cleared and address critical cardiac health needs.

Pricing & Value

FibriCheck

FibriCheck offers transparent pricing for both end-users via subscriptions and for healthcare providers through licensing agreements, allowing for clear cost assessment. ELEFT's pricing is only available upon contacting sales and is part of an enterprise platform, making its value proposition less immediately clear and likely geared towards larger institutional budgets.

Enterprise Readiness

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT explicitly states it is part of Eko's SENSORAu2122 platform, an enterprise solution, and confirms it has a Business Associate Agreement (BAA) and is HIPAA compliant. While FibriCheck is HIPAA compliant and offers a professional portal with licensing agreements, its BAA is only implied, giving ELEFT a slight edge in formal enterprise deployment assurance.

Innovation

FibriCheck

FibriCheck demonstrates greater innovation by leveraging ubiquitous smartphone camera technology for medical-grade heart rhythm monitoring, democratizing access to cardiac screening. ELEFT innovates by augmenting a traditional medical device (stethoscope) with AI, which is valuable but less disruptive in its approach to patient-centric data collection.

Support & Docs

Tie

Both Eko Health and FibriCheck provide comprehensive support resources, including online help centers, FAQs, user manuals, and contact options for assistance. Based on publicly available information, neither tool demonstrates a significantly superior offering in terms of support and documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Eko Low Ejection Fraction Tool (ELEFT) FibriCheck
Name Eko Low Ejection Fraction Tool (ELEFT) FibriCheck
Company Eko Health Qompium nv
Primary Detection Target Low ejection fraction (indicator of heart failure) Arrhythmias (e.g., Atrial Fibrillation)
Required Device/Integration Eko digital stethoscopes Smartphone camera
Primary User Focus Clinicians (during routine physical exams) Patients (for self-monitoring), with a healthcare professional portal

Videos

Demos, reviews, and walkthroughs featuring Eko Low Ejection Fraction Tool (ELEFT) and FibriCheck.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

ELEFT integrates into routine physical exams, using Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, in approximately 15 seconds. FibriCheck is a patient-facing mobile application that enables self-monitoring of heart rhythm for arrhythmia detection, with a healthcare professional portal for review and management of patient data.
ELEFT is part of Eko's SENSORAu2122 platform, which involves cloud-based data processing and storage, but specific EHR integration capabilities are not detailed in the provided information. FibriCheck offers API-based integration into existing EHRs, RPM platforms, and population health systems, with a provider portal to review patient data.
ELEFT's AI algorithm, validated in a multi-site study of 3,456 patients, achieved a sensitivity of 74.7% and a specificity of 77.5% for detecting LVEF less than or equal to 40%. FibriCheck's AI algorithm for AFib detection has demonstrated high overall performance, with an accuracy of 98.5%, sensitivity of 96.3%, and specificity of 99.3% in a multicenter validation study.
ELEFT is particularly impactful for non-invasive screening of heart failure risk during routine physical exams, especially in primary care settings where traditional echocardiography may be less accessible. FibriCheck is effective for early detection and ongoing monitoring of irregular heart rhythms, including AFib, in patients experiencing palpitations or those at risk due to conditions like high blood pressure or diabetes.
ELEFT integrates with Eko digital stethoscopes, which clinicians are already familiar with, and provides results in approximately 15 seconds, suggesting a rapid learning curve and quick time-to-value for point-of-care screening. FibriCheck involves a patient-facing app and a healthcare professional portal, requiring patient onboarding and staff familiarity with the dashboard for reviewing remote monitoring data to realize clinical value.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.